These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 29379211)

  • 1. Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.
    Walker LM; Burton DR
    Nat Rev Immunol; 2018 May; 18(5):297-308. PubMed ID: 29379211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New technologies in therapeutic antibody development: The next frontier for treating infectious diseases.
    Keating SM; Higgins BW
    Antiviral Res; 2024 Jul; 227():105902. PubMed ID: 38734210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies for the prevention and treatment of viral diseases.
    Sawyer LA
    Antiviral Res; 2000 Aug; 47(2):57-77. PubMed ID: 10996394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
    Both L; Banyard AC; van Dolleweerd C; Wright E; Ma JK; Fooks AR
    Vaccine; 2013 Mar; 31(12):1553-9. PubMed ID: 23370150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
    Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
    Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Zoonotic infection with simian foamy viruses: potent neutralizing antibodies].
    Buseyne F
    Virologie (Montrouge); 2019 Feb; 23(1):35-39. PubMed ID: 31131828
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow.
    Garraud O; Heshmati F; Pozzetto B; Lefrere F; Girot R; Saillol A; Laperche S
    Transfus Clin Biol; 2016 Feb; 23(1):39-44. PubMed ID: 26775794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibody-Based Drugs and Other Recombinant Proteins for Diagnostics and Therapy of Viral Infections, Autoimmune Diseases and Cancer].
    Kuprash DV; Garib FY; Nedospasov SA
    Mol Biol (Mosk); 2017; 51(6):883-885. PubMed ID: 29271953
    [No Abstract]   [Full Text] [Related]  

  • 9. Human monoclonal antibodies for discovery, therapy, and vaccine acceleration.
    Andreano E; Seubert A; Rappuoli R
    Curr Opin Immunol; 2019 Aug; 59():130-134. PubMed ID: 31450054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases.
    Chanock RM; Crowe JE; Murphy BR; Burton DR
    Infect Agents Dis; 1993 Jun; 2(3):118-31. PubMed ID: 8173784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating antibody insights.
    Gerberding JL
    Science; 2013 Sep; 341(6151):1151. PubMed ID: 24030986
    [No Abstract]   [Full Text] [Related]  

  • 12. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
    Jaworski JP; Cahn P
    Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis.
    Clementi N; Criscuolo E; Castelli M; Clementi M
    New Microbiol; 2012 Oct; 35(4):399-406. PubMed ID: 23109007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).
    Cabral TM; Berhane Y; Schmidt L; Tracz DM; Hole K; Leith M; Corbett CR
    J Virol Methods; 2012 Jul; 183(1):25-33. PubMed ID: 22575685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiviral humanized and human monoclonal antibodies].
    Lashkevich VA
    Vopr Virusol; 2011; 56(5):4-8. PubMed ID: 22171470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.
    Zanin M; Keck ZY; Rainey GJ; Lam CY; Boon AC; Rubrum A; Darnell D; Wong SS; Griffin Y; Xia J; Webster RG; Webby R; Johnson S; Foung S
    J Virol; 2015 Apr; 89(8):4549-61. PubMed ID: 25673719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis of Human Parechovirus Neutralization by Human Monoclonal Antibodies.
    Shakeel S; Westerhuis BM; Ora A; Koen G; Bakker AQ; Claassen Y; Wagner K; Beaumont T; Wolthers KC; Butcher SJ
    J Virol; 2015 Sep; 89(18):9571-80. PubMed ID: 26157123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly neutralizing antibodies and the promise of universal vaccines: where are we now?
    Hefferon KL
    Immunotherapy; 2014; 6(1):51-7. PubMed ID: 24341884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monoclonal antibodies in diseases of viral origin].
    Aguilar Setién A; Kretschmer R
    Salud Publica Mex; 1985; 27(3):251-9. PubMed ID: 2996158
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity.
    Jia Q; Ng Q; Chin W; Meng T; Chow VTK; Wang CI; Kwang J; He F
    Sci Rep; 2017 Apr; 7():46402. PubMed ID: 28422137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.